@AllofUsResearch HM: https://t.co/lLcGwe4ZHc CYP2D6 implicated for fluoxetine and CYP2C19 for other SSRIs.
2/n We know that antidepressants can be helpful for treating depression, but the journey to find one that works can be long. Genetic testing could act as a short cut, and there are even guidelines for it! https://t.co/t5XKxmNMfA https://t.co/Vr5FZ2SfNg @KN
RT @mueller_dj: @shrews11 @NEJM These are actually genes belonging to the pharmacokinetic compartment. Variations in these genes are assoc…
@shrews11 @NEJM These are actually genes belonging to the pharmacokinetic compartment. Variations in these genes are associated with efficacy; see for example: https://t.co/1Q7GoDjA3u https://t.co/LIQ25dkZhX https://t.co/OXbRJZBgZ0 https://t.co/gXhdfP2onf
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. Read more here: h
@evolvability @DebbieKennett I was actually shocked to see that several of those SSRI / cytochrome variants are cleared by the FDA : https://t.co/9KdhHO2xzQ
Publicada la actualización guía CPIC d dosificación d inhibidores d recaptación d serotonina y genotipo CYP2D6 y 2C19 http://t.co/b9cAoSj2vf
Publicada la actualización guía CPIC d dosificación d inhibidores d recaptación d serotonina y genotipo CYP2D6 y 2C19 http://t.co/b9cAoSj2vf